About the Cover
Chemokines are chemotactic cytokines with multifaceted roles in tumor development. The chemokine superfamily consists of approximately 50 endogenous chemokine ligands and 20 G-protein–coupled receptors, mediating the host response to cancer by directing the trafficking of leukocytes into the tumor microenvironment and inducing the development and maturation of lymphoid effector cells. Chemokines produced by tumor cells, intratumor stromal cells, and intratumor leukocytes can attract different immune cells into the tumor bed, and the composition of immune effector and suppressor cells in the tumor can affect the outcome of tumor development. Chemokines released by tumor cells, stromal cells, and leukocytes can directly affect the growth and survival of tumor cells by their angiogenic or angiostatic activity by inducing the release of tumor-promoting growth factors that can act in a paracrine fashion to promote tumor growth and by inducing the migration of tumor cells to distant sites for the development of metastasis. For details see the Masters of Immunology primer by Melvyn T. Chow and Andrew D. Luster on page 1125 of this issue.

About the Master
Andrew D. Luster, MD, PhD, is the Persis, Cyrus, and Marlow B. Harrison Professor of Medicine at Harvard Medical School (HMS) and the E. Alexandria and Michael N. Altman Chair in Immunology at Massachusetts General Hospital (MGH). He received his BS in Biology summa cum laude from Duke University, his PhD in molecular genetics and immunology from the Rockefeller University, and his MD from Cornell University Medical College. Dr. Luster was a medical resident and infectious disease fellow in the Department of Medicine at MGH and a research fellow in the HMS Department of Genetics. In 1994, Dr. Luster established his independent laboratory at MGH. He was appointed chief of a new MGH division, the Division of Rheumatology, Allergy, and Immunology, and was named director of the new Research Center for Immunology and Inflammatory Diseases in 2000.
Dr. Luster is a quintessential medical scientist–a clinician with solid training in basic science. Over the past three decades, he has been intimately associated with the birth, growth, and development of the chemokine field. He performed his PhD research in the laboratories of Drs. Jeffrey Ravetch and Zanvil Cohn, identifying the interferon-γ inducible cytokine IP-10 and characterizing its molecular regulation. He continued his training in the fundamentals of basic science research as a postdoctoral fellow in Dr. Philip Leder's laboratory (HMS), studying the in vivo antitumor activity of the CXC chemokine IP-10 and defining the biologic activity of the CC chemokine eotaxin, an eosinophil chemoattractant. Dr. Luster has made multiple seminal contributions to our understanding of the roles of the chemokine family of immunoregulatory chemotactic cytokines in health and diseases since his initial discovery of the T-cell chemoattractant IP-10 (now also called CXCL10). His laboratory has helped define the chemokine family and its functions in immune-cell trafficking, which is necessary to generate innate and adaptive immune responses, and in the pathogenesis of immune and inflammatory diseases.
Dr. Luster is an outstanding teacher; he has taught many medical and immunology classes and has mentored over 60 clinical and basic science trainees from around the world. He is a reviewer for numerous peer-review journals and a member of various scientific advisory boards. Dr. Luster has received many awards and honors, including a Damon Runyon–Walter Winchell Postdoctoral Fellowship, a Cancer Research Institute Investigator Award, a Culpeper Medical Scientist Award, an NIH MERIT Award, and the 2011 Lee C. Howley Sr. Prize for Arthritis Research from the Arthritis Foundation. He is an elected member of the American Society for Clinical Investigation, the Interurban Clinical Club, and the American Association of Physicians.